A Vaccine Study for High Risk Cancers

Penn State University

Overview

The purpose of this study is to determine the safety and immunological effects of a vaccine for people diagnosed with high risk neuroblastoma, osteogenic sarcoma, and rhabdomyosarcoma. It is hypothesized that this vaccine could reduce the incidence of relapse.

MAGE -A1, MAGE- A3, and NY-ESO-1 are antigens that can be found with significant frequency on neuroblastoma, rhabdomyosarcoma, and osteogenic sarcoma, three relatively common solid tumors that in some cases can be associated with a high risk for relapse. In this study each subject will be screened for the presence of these antigens, and an individualized vaccine will be developed and administered using the subject's own dendritic cells (DC). This study consists of two phases: a screening phase and a treatment/vaccine phase. First, eligible individuals will be consented into the screening phase. Tumor specimens will be tested by immunohistochemistry or RT-PCR for the presence of MAGE- A1, MAGE- A3, and NY-ESO-1. Those testing positive for one or more antigen can be consented for the treatment phase of the study. Blood will be drawn for DC culture, and approximately one month later a series of three vaccines will be administered at two week intervals. Subjects will receive a topical medication called imiquimod to the vaccine site prior to and following each injection, to help immune cells travel into the area. Study participation occurs over 18 months and also involves periodic physical examinations and blood draws.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Neuroblastoma Rhabdomyosarcoma Osteogenic Sarcoma

Interventions

MAGE-A1, MAGE-A3, and NY-ESO-1 VaccineBIOLOGICAL

A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.

Eligibility

Sex: ALLMin age: 1 YearMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria for Screening Phase: Patient 1 to 70 years of age with neuroblastoma, rhabdomyosarcoma, or osteogenic sarcoma, who have one or more of the following high risk features: * Neuroblastoma: * Stage IV disease * Stage III disease with n-myc amplification * Osteogenic sarcoma: * Presence of metastases * Elevated alkaline phosphatase or LDH at diagnosis * Primary tumor affecting the axial skeleton * Poor histopathological response after completion of pre-surgical chemotherapy (≥10% viable tumor) * Rhabdomyosarcoma: * Stage IV disease * Alveolar histology * Positive tumor margins, with lymph node positivity Inclusion Criteria for Vaccine Phase: * Patient meets all screening criteria and tumor is positive for NY-ESO-1, MAGE- A1, or MAGE-A3 by immunohistochemistry or RT-PCR. * Patients who are between 3 months and 2 years following the completion of therapy, and have achieved at least a very good partial response to primary therapy. * No chemotherapy is planned for one month following the last vaccination. * Bilirubin \<2 mg/dL, and SGOT/SGPT \<2.5 x normal * Creatinine clearance \> 50ml/min as estimated by patient's serum creatinine, weight, and age * Room air pulse oximetry \>94% * Patient is not pregnant * Male and female sexually active patients of reproductive who wish to participate must agree to use acceptable contraception * Patient is not moribund and has a projected life expectancy \>6 months * Lansky performance scale \> 70, ECOG \< 2 (Appendix I) * Potential subjects will be tested for HIV 1 and 2 antibodies, HTLV 1/2 antibodies, and for HIV 1, hepatitis C and hepatitis B virus by NAT testing. - -Subjects testing positive for any of these pathogens will be ineligible for vaccine. * White blood cells ≥ 2.5 K/µL, Hemoglobin ≥ 8 g/dL, Hematocrit \> 25%, and Platelets ≥ 70 K/µL * Patient does not have central nervous system involvement. * Patient does not a have a history of autoimmune disease, specifically inflammatory bowel disease, systemic lupus erythematosis, or rheumatoid arthritis * Patient is not receiving concurrent systemic steroid therapy * Patient does not have a known systemic hypersensitivity to imiquimod or any vaccine component

Outcomes

Primary Outcomes

The primary objective is to determine if there is an amplification or new development of NY-ESO-1, MAGE-A1, or MAGE-A3 specific CD4+ or CD8+ T cells post-vaccination.

Time frame: 2 years

Secondary Outcomes

The investigators will determine the safety of vaccine and imiquimod administration in these patients.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.